Joseph D. Khoury

Joseph D. Khoury's AcademicInfluence.com Rankings

Joseph D. Khoury

Philosophy

#7621

World Rank

#10860

Historical Rank

Logic

#4668

World Rank

#5987

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Joseph D. Khoury's Degrees

Doctorate Medicine Johns Hopkins University

Why Is Joseph D. Khoury Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joseph D. Khoury's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022) (373)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022) (293)
Ewing Sarcoma Family of Tumors (2005) (257)
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. (2016) (224)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. (2015) (216)
Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq (2013) (180)
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. (2004) (164)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. (2018) (155)
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease (2017) (149)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. (2018) (137)
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. (2016) (130)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2013) (124)
Molecular Characterization of the Pediatric Preclinical Testing Panel (2008) (116)
CD56+ TdT+ blastic natural killer cell tumor of the skin (2002) (114)
Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. (2003) (112)
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells (2018) (110)
TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow (2013) (107)
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors (2008) (103)
Expression of Mcl‐1 in mantle cell lymphoma is associated with high‐grade morphology, a high proliferative state, and p53 overexpression (2003) (97)
Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray (2004) (96)
Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients (2015) (93)
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells (2006) (89)
Diffuse large B-cell lymphoma variants: an update. (2019) (86)
Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations (2014) (82)
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage (2018) (82)
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (2020) (80)
Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma (2006) (74)
MYC/BCL6 double‐hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis (2016) (73)
Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. (2004) (72)
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia (2017) (71)
Telangiectatic osteosarcoma: The St. Jude Children's Research Hospital's experience (2007) (71)
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. (2018) (68)
Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes (2017) (66)
Desmoplastic small round cell tumor in childhood: The St. Jude Children's Research Hospital experience (2007) (66)
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression (2018) (65)
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma (2017) (65)
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution (2014) (64)
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease (2019) (59)
Cytogenetic findings in blastoid mantle cell lymphoma. (2003) (59)
Angiosarcomas Arising in the Viscera and Soft Tissue of Children and Young Adults: A Clinicopathologic Study of 15 Cases (2009) (56)
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation (2018) (55)
RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. (2019) (55)
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial (2017) (55)
Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine. (2019) (53)
Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation (2017) (51)
Crystal‐storing histiocytosis: a clinicopathological study of 13 cases (2016) (50)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells (2019) (48)
Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm (2019) (46)
Prognostic impact of CD5 expression in diffuse large B‐cell lymphoma in patients treated with rituximab‐EPOCH (2017) (41)
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia (2018) (41)
Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) (2013) (39)
MRI and biologic behavior of desmoid tumors in children. (2007) (39)
Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. (2010) (39)
Ewing sarcoma‐family tumors that arise after treatment of primary childhood cancer (2006) (38)
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis (2015) (37)
MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas (2018) (37)
Pediatric Cutaneous Angiosarcomas: A Clinicopathologic Study of 10 Cases (2011) (37)
The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma. (2002) (36)
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia (2018) (36)
Epstein-Barr Virus in Lymphoproliferative Processes: An Update for the Diagnostic Pathologist (2009) (35)
Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. (2013) (35)
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia (2017) (34)
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas (2020) (34)
Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection (2019) (34)
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy (2020) (34)
Pure erythroid leukemia (2017) (33)
Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. (2016) (33)
Targeted delivery of NRASQ61R and Cre‐recombinase to post‐natal melanocytes induces melanoma in Ink4a/Arflox/lox mice (2010) (32)
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild‐type RAS (2014) (31)
Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents (2010) (31)
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma (2020) (31)
Erythroleukemia-historical perspectives and recent advances in diagnosis and management. (2017) (30)
Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2019) (30)
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis (2015) (30)
Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer (2014) (30)
Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma (2017) (30)
Next-generation companion diagnostics: promises, challenges, and solutions. (2015) (29)
Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. (2005) (29)
Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a ten-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm (2020) (29)
De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis (2015) (29)
Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (2016) (29)
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. (2020) (29)
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. (2018) (29)
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML (2018) (28)
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors (2015) (28)
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma (2019) (28)
Epstein–Barr virus‐positive plasmacytoma in immunocompetent patients (2015) (28)
MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. (2015) (27)
A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation (2018) (27)
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine (2021) (27)
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. (2018) (27)
CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases (2015) (27)
Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of γδ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With αβ T-Cell Large Granular Lymphocytic Leukemia. [corrected]. (2015) (27)
Artificial Intelligence and Digital Microscopy Applications in Diagnostic Hematopathology (2020) (27)
Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations (2017) (26)
Tumors of Lymphoid and Hematopoietic Tissues (2015) (26)
Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents (2017) (26)
Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases. (2010) (26)
B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma (2013) (26)
A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma (2019) (26)
p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor. (2009) (25)
Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. (2018) (25)
Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience (2018) (25)
Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. (2018) (25)
ICAM-2 Expression Mediates a Membrane-Actin Link, Confers a Nonmetastatic Phenotype and Reflects Favorable Tumor Stage or Histology in Neuroblastoma (2008) (24)
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens (2018) (24)
Osteosarcoma Among Children Aged 5 Years or Younger: The St. Jude Children's Research Hospital Experience (2006) (24)
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations (2018) (24)
Blastic Plasmacytoid Dendritic Cell Neoplasm (2018) (23)
Myeloid neoplasms with concurrent BCR‐ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm (2017) (23)
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival (2019) (22)
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia (2022) (22)
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution (2018) (22)
Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics (2008) (22)
Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations (2018) (21)
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN) (2019) (21)
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia (2017) (21)
Simultaneous deletion of 3′ETV6 and 5′EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review (2016) (20)
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia (2021) (20)
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) (2022) (20)
Grading of Non-Rhabdomyosarcoma Soft Tissue Sarcoma in Children and Adolescents: A Comparison of Parameters Used for the FNCLCC and POG systems (2010) (20)
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors (2021) (20)
T Cell/Histiocyte-Rich Large B-Cell Lymphoma (2013) (19)
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy (2019) (18)
Significance of pleural effusion in neuroblastoma (2007) (18)
Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study (2020) (17)
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia (2014) (17)
Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. (2021) (17)
Chronic lymphoproliferative disorder of NK‐cells: A single‐institution review with emphasis on relative utility of multimodality diagnostic tools (2018) (17)
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) (2018) (16)
Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia (2020) (16)
Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies (2015) (16)
Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis (2019) (16)
High-grade Transformation of Low-grade B-cell Lymphoma: Pathology and Molecular Pathogenesis (2016) (16)
Lymphoplasmacytic Lymphoma and Waldenstrom Macroglobulinemia (2013) (16)
TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. (2019) (15)
Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. (2019) (15)
Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. (2019) (15)
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS (2022) (15)
Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center. (2016) (15)
Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement (2018) (15)
Chronic Epstein Barr virus infection leading to classical Hodgkin lymphoma (2016) (15)
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms (2017) (15)
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens (2017) (14)
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survival (2018) (14)
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells (2021) (14)
MYC rearrangement and MYC/BCL2 double expression but not cell‐of‐origin predict prognosis in R‐CHOP treated diffuse large B‐cell lymphoma (2020) (14)
Coactivation of NF-κB and Notch signaling is sufficient to induce B cell transformation and enables B-myeloid conversion. (2019) (14)
Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma (2004) (14)
Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia (2015) (14)
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia (2016) (14)
Focal Rosai–Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation (2018) (14)
Cholangiocyte apoptosis is an early event during induced metamorphosis in the sea lamprey, Petromyzon marinus L. (2010) (13)
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. (2021) (13)
Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments (2009) (13)
Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia (2021) (13)
ALK-positive anaplastic large cell lymphoma (2020) (13)
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study (2018) (13)
Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. (2019) (12)
Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study (2020) (12)
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (2019) (12)
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. (2015) (12)
Histiocytic sarcoma: secondary neoplasm or "transdifferentiation" in the setting of B-acute lymphoblastic leukemia. (2016) (12)
Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer (2019) (12)
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse (2022) (12)
Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. (2021) (12)
Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation (2018) (12)
A Single Case of Rosai–Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine (2014) (12)
Multicentric Castleman Disease (2013) (11)
Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia (2021) (11)
Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function* (2020) (11)
PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm (2019) (11)
CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies (2020) (11)
Reconsideration of the first recognition of breast implant-associated anaplastic large cell lymphoma: A critical review of the literature. (2020) (11)
Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature (2017) (11)
Primary Mediastinal (Thymic) Large B-Cell Lymphoma (2013) (11)
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. (2016) (11)
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. (2013) (10)
Clinical significance of acquired loss of the X chromosome in bone marrow. (2016) (10)
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. (2015) (10)
Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML). (2019) (10)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era (2019) (10)
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1 (2020) (10)
Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update (2020) (10)
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience (2021) (10)
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma (2021) (10)
Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients (2022) (10)
Composite thymoma and chronic lymphocytic leukemia/small lymphocytic lymphoma involving the anterior mediastinum. (2003) (10)
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis (2018) (9)
Accuracy of diagnosing mantle cell lymphoma and identifying its variants on fine‐needle aspiration biopsy (2018) (9)
Aggressive NK Cell Leukemia: Current State of the Art (2020) (9)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes (2015) (9)
Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa‐associated Lymphoid Tissue (2019) (9)
Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications (2019) (9)
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure? (2016) (9)
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. (2019) (9)
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure (2019) (9)
Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases (2022) (9)
Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT 3 in ALK and ALK Anaplastic Large Cell Lymphoma (2003) (9)
Cystic sclerosing haemangioma of the lung (2003) (9)
Recent Updates on Chronic Myelomonocytic Leukemia (2018) (8)
Prediction of survival with intensive chemotherapy in acute myeloid leukemia (2022) (8)
Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate. (2010) (8)
The evolving potential of companion diagnostics (2016) (8)
Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. (2017) (8)
Atlas of lymph node pathology (2013) (8)
Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. (2017) (8)
Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. (2019) (8)
A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis (2020) (8)
Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens (2017) (8)
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. (2022) (8)
Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists (2016) (8)
Immunopathology of Kikuchi–Fujimoto disease: A reappraisal using novel immunohistochemistry markers (2019) (8)
Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2017) (8)
T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid (2020) (8)
Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults (2015) (8)
Nephroblastic neoplasms. (2005) (8)
Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification. (2022) (8)
Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions (2021) (8)
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 (2022) (7)
Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation (2021) (7)
Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. (2018) (7)
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features (2020) (7)
Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm (2021) (7)
Cyclin D1 expression in Rosai-Dorfman disease: A near constant finding that is not invariably associated with MAPK/ERK pathway activation. (2022) (7)
Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma (2017) (7)
Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations (2018) (7)
CLL progression after one cycle of FCR: Richter's transformation versus EBV‐associated lympho‐proliferation (2017) (7)
Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies (2016) (7)
Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma (2020) (7)
Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (7)
Disseminated blastic plasmacytoid dendritic cell neoplasm. (2015) (7)
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD (2022) (6)
Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. (2004) (6)
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. (2016) (6)
Sensitivity of fine-needle aspiration biopsy for diagnosing and grading follicular lymphomas using a multiparameter approach in a cancer center. (2017) (6)
Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms (2017) (6)
Chronic myeloid leukemia with insertion-derived BCR–ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis (2020) (6)
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. (2021) (6)
Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment (2016) (5)
Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome (2019) (5)
Diamond-Blackfan Anemia Predisposing to Myelodysplastic Syndrome in Early Adulthood. (2017) (5)
Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis (2021) (5)
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification (2022) (5)
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax (2020) (5)
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia (2020) (5)
Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies (2020) (5)
Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria (2018) (5)
MPN-377: Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis (2020) (5)
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia (2021) (5)
Vascular Transformation of Lymph Node Sinuses (2013) (5)
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis (2020) (5)
Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells (2018) (5)
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis (2020) (5)
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. (2022) (5)
Germline DNMT3A mutation in familial acute myeloid leukaemia (2020) (5)
Development of TP53 mutations over the course of therapy for acute myeloid leukemia (2021) (5)
A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy (2021) (4)
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis (2017) (4)
Epithelial Inclusions in Lymph Node (2013) (4)
Lymphocyte-Rich Classical Hodgkin Lymphoma (2013) (4)
Genome‐wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patients (2019) (4)
PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS (2019) (4)
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System (2022) (4)
Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia (2017) (4)
Human Immunodeficiency Virus Lymphadenitis (2013) (4)
Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (4)
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse (2021) (4)
Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles (2019) (4)
Unusual breast mass: lymphoma with crystal-storing histiocytosis. (2015) (4)
Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. (2020) (4)
Characteristics and clinical implications of reactive germinal centers in the bone marrow. (2017) (4)
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD) (2019) (4)
Epstein–Barr virus‐positive follicular lymphoma (2018) (4)
Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor (2020) (4)
Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation (2020) (4)
Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience (2020) (3)
Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy (2021) (3)
Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing (2019) (3)
Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial (2020) (3)
Social Media for Hematopathologists: Medical Practice Reinvented—#Hemepath (2020) (3)
Immunopathology of Kikuchi‐Fujimoto Disease: A reappraisal using novel immunohistochemistry combinations (2019) (3)
Angioimmunoblastic T-Cell Lymphoma (2013) (3)
Lymphoproliferative Disorders Associated with Primary Immune Disorders (2013) (3)
Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial (2020) (3)
Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies (2019) (3)
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. (2020) (3)
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes (2022) (3)
Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs) (2019) (3)
B‐cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T‐cell precursor acute lymphoblastic leukaemia/lymphoma (ETP‐ALL/LBL) from other subtypes of T‐cell ALL/LBL (2021) (3)
Normal Lymph Node Architecture and Function (2013) (3)
TAM kinases as regulators of cell death. (2021) (3)
Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia (2022) (3)
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (2016) (3)
Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia (2020) (3)
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells (2022) (3)
B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma. (2020) (3)
Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow (2021) (3)
CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. (2020) (2)
Hemophagocytic Lymphohistiocytosis/Hemophagocytic Syndromes (2013) (2)
Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma (2022) (2)
Unicentric Castleman Disease (2013) (2)
Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells (2016) (2)
ALK-positive large B-cell lymphoma (2020) (2)
Epstein - Barr virus infection in de novo diffuse large B-cell lymphoma in Jordan and Turkey. (2019) (2)
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. (2022) (2)
Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes. (2014) (2)
Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. (2022) (2)
Prolactinoma as the first manifestation of Gardner's syndrome (2008) (2)
hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation (2016) (2)
Call for revision of College of American Pathologists-mandated requirements for retention of laboratory records and materials. (2008) (2)
Radiation Therapy for Refractory High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements (2020) (2)
Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2021) (2)
Expression of the Macrophage-Associated Antigen CD68/KP1 by Tumor Cells of Sarcomatoid Renal Cell Carcinoma (1999) (2)
Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant (2022) (2)
Nodular Lymphocyte-Predominant Hodgkin Lymphoma (2013) (2)
Pediatric malignancies: Pathology and imaging (2015) (2)
Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms (2018) (2)
Mycobacterial Spindle Cell Pseudotumor (2013) (2)
Myeloid diseases in the lung and pleura. (2020) (2)
Mantle Cell Lymphoma (1996) (2)
B-prolymphocytic leukemia: Is it time to retire this entity? (2021) (2)
A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (2017) (2)
CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management (2021) (2)
Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon (2021) (2)
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update (2022) (2)
Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy (2019) (2)
Allogeneic cord blood regulatory T cells can resolve lung inflammation. (2022) (2)
Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. (2021) (2)
Primary Gastric Diffuse Large B-Cell Lymphoma Treated with Abbreviated Chemoimmunotherapy and Contemporary Radiation Therapy has Excellent Outcomes with Minimal Toxicity (2018) (2)
Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm (2022) (2)
Hydroa Vacciniforme-Like Lymphoproliferative Disorder With Progression to EBV+ Cytotoxic Peripheral T-Cell Lymphoma. (2020) (2)
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in era of tyrosine kinase inhibitors (2015) (2)
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement (2019) (2)
Mycobacterium Tuberculosis Lymphadenitis (2013) (2)
Bacterial (Suppurative) Lymphadenitis (2013) (2)
CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations. (2021) (1)
Chronic lymphocytic leukemia with plasmacytic differentiation (2019) (1)
Reactive Paracortical Hyperplasia (2013) (1)
Bacillary Angiomatosis of Lymph Nodes (2013) (1)
Reactive Follicular Hyperplasia (2013) (1)
ALL-315: Outcome of Adults with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (2020) (1)
CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study (2020) (1)
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. (2022) (1)
Nodular sclerosis Hodgkin lymphoma (2021) (1)
The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis (2021) (1)
Metabolic/histologic characterization of pediatric CNS neoplasms (2007) (1)
Starry Sky Pattern in Hematopoietic Neoplasms: A Review of Pathophysiology and Differential Diagnosis (2016) (1)
Chronic Myelomonocytic Leukemia: Hematopathology Perspective. (2021) (1)
Single Injection of Cord Blood Regulatory T Cells Can Delay the Manifestations of Systemic Lupus Erythematosus (2019) (1)
MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy (2022) (1)
Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). (2016) (1)
Chronic Granulomatous Lymphadenitis (2013) (1)
Artificial Intelligence-Assisted Mapping of Proliferation Centers in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Identifies Patterns That Reliably Distinguish Accelerated Phase and Large Cell Transformation (2021) (1)
Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) (2021) (1)
Future of Education or Present Reality: MD Anderson Cancer Center Hematopathology Virtual Educational Platform under Coronavirus Disease 2019 (COVID-19) Pandemic. (2021) (1)
Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML (2021) (1)
p 18 Ink 4 c and p 53 Act as Tumor Suppressors in Cyclin D 1 – Driven Primitive Neuroectodermal Tumor (2009) (1)
Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment (2016) (1)
Epstein–Barr Virus–Positive Diffuse Large B-Cell Lymphoma of the Elderly (2013) (1)
The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency (2022) (1)
Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells (2019) (1)
From the archives of MD Anderson Cancer Center Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. (2020) (1)
AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells (2016) (1)
7. Additional structural chromosomal abnormalities have a negative prognostic effect in patients with inv(16)/t(16;16) acute myeloid leukemia (AML) (2019) (1)
Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)). (2016) (1)
Low-Dose (4 Gy) Radiation Therapy as an Effective Treatment Modality for Relapsed Refractory Mantle Cell Lymphoma (2018) (1)
Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering (2022) (1)
Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. (2021) (1)
Lymphadenopathy Secondary to Drug-Induced Hypersensitivity Syndrome (2013) (1)
T-Cell Lymphoma Clonality by Copy Number Variation Analysis of T-Cell Receptor Genes (2021) (1)
Follicular Dendritic Cell Sarcoma (2013) (1)
CellSpatialGraph: Integrate hierarchical phenotyping and graph modeling to characterize spatial architecture in tumor microenvironment on digital pathology (2021) (1)
Lymphadenopathy Associated with Joint Prostheses (2013) (1)
Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. (2021) (1)
Post-transplant Lymphoproliferative Disorder: Monomorphic T/NK-Cell, and Classical Hodgkin Lymphoma (2013) (1)
Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression (2020) (1)
Mixed cellularity Hodgkin lymphoma (2021) (0)
In Reply. (2017) (0)
Langerhans Cell Sarcoma (2013) (0)
Rheumatoid Arthritis-Related Lymphadenopathy (2013) (0)
Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression (2020) (0)
Lymphadenopathy in IgG4-Related Disease (2013) (0)
Interdigitating Dendritic Cell Sarcoma (2013) (0)
Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosome-Negative ALL: Relationship with Minimal Residual Disease Status (2016) (0)
Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor (2016) (0)
Adult T-Cell Leukemia/Lymphoma (2013) (0)
Bone Marrow Synoptic Reporting for Hematologic Neoplasms (2016) (0)
Mast Cell Disease (2013) (0)
Acute Myeloid Leukemia with t(v;5q33-34) Does Not Always have Myelodysplastic Features but is Associated with Poor Outcome (2015) (0)
Epstein-Barr virus in lymphoproliferative processes: An update for the diagnostic pathologist (Advances in Anatomic Pathology (2009) 16, (40-55)) (2009) (0)
Colonic myeloid sarcoma with mutated NPM1 manifesting with ulceration (2022) (0)
Fungal Lymphadenitis: Histoplasma, Cryptococcus, and Coccidioides (2013) (0)
Progressive Transformation of Germinal Centers (2013) (0)
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR) (2019) (0)
Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in Acute Myeloid Leukemia (2020) (0)
Simultaneous deletion of 3′ETV6 and 5′EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review (2016) (0)
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes (2020) (0)
Metastases to Lymph Nodes (2013) (0)
Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. (2018) (0)
Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (0)
Herpes Simplex Virus Lymphadenitis and Varicella-Herpes Zoster Lymphadenitis (2013) (0)
ALL-216: Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy (2020) (0)
MYC, BCL2 AND BCL6 COEXPRESSION PATTERNS AT SINGLE‐CELL RESOLUTION RE‐DEFINE DOUBLE EXPRESSOR LYMPHOMAS (2021) (0)
Value of Immunohistochemistry-Based Direct Visualization for Localization, Lineage Determination and Monitoring of IDH1 p.R132H Mutant Clones in AML (2016) (0)
Abstract 4030: Efficacy of novel combination therapy against AML cells with mutant NPM1 (2022) (0)
Abstract PO-35: Prognostic significance of MYC, BCL2, and BCL6 colocalization at single-cell resolution in DLBCL (2020) (0)
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations (2022) (0)
Splenic B-Cell Marginal Zone Lymphoma in Lymph Node (2013) (0)
MPN-400: Exploring the Molecular Grey Zone of Myeloid Neoplasms: Concurrent SRSF2 and Classic MPN Driver Mutations (2020) (0)
Therapy-Related Myeloid Neoplasms in Breast Cancer Patients: A Single-Institution Report of 150 Cases (2014) (0)
7154 Clinical significance of non-neoplastic lesions of the ampulla of vater. (2000) (0)
Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic Syndromes (2020) (0)
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. (2022) (0)
The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL) (2017) (0)
Preclinical Efficacy of a Novel Omacetaxine-Based Therapy for AML Expressing Somatic or Germline Mutant RUNX1 (2020) (0)
Assessing the Role of Radiation Therapy for Primary Mediastinal Large B-Cell Lymphoma in the Setting of PET Avid Disease after Chemotherapy (2020) (0)
Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis (2020) (0)
Hematopathology: Poster#206 PLASMABLASTIC LYMPHOMA A SERIES OF 31 PATIENTS FROM A SINGLE INSTITUTION (2014) (0)
Author reply (0)
Cord Blood Regulatory T Cells for Prevention of Graft Versus Host Disease (2017) (0)
126. MECOM rearrangement by Pericentric Inversion 3 presents a diagnostic challenge (2022) (0)
Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL) (2019) (0)
Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation (2018) (0)
Whipple Disease Lymphadenitis (2013) (0)
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. (2023) (0)
Lymphomas Associated with FGFR1 Abnormalities (2013) (0)
Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study (2020) (0)
PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia (2022) (0)
The current World Health Organization ( WHO ) classification of hematopoietic malignancies defines several types of mature T-cell leukemia including T-cell prolymphocytic leukemia (2004) (0)
The Impact of PET-CT on Rates of Progression from Solitary Plasmacytoma to Multiple Myeloma after Definitive Radiation Therapy (2019) (0)
Monomorphic B-Cell (Including Plasmacytic) Post-transplant Lymphoproliferative Disorder (2013) (0)
48. ALK tissue FISH in lung cancer: The MDACC experience (2021) (0)
Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases. (2014) (0)
Lymphomas Associated with HIV Infection (2013) (0)
Unusual case of human herpesvirus 8‐positive large B‐cell lymphoma associated with Castleman disease (2019) (0)
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. (2023) (0)
Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study (2022) (0)
Molecular Characterization Using Oncoscan Chromosome Microarray in an International Cohort of 51 Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2021) (0)
Cutaneous Anaplastic Large Cell Lymphoma with Dissemination to Lymph Nodes and Other Sites (2013) (0)
Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice (2017) (0)
MPN-379: Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML) (2020) (0)
AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells (2019) (0)
Characteristics of therapy-related myeloid neoplasms in breast cancer patients (2015) (0)
Ewing Sarcoma Family of Tumors Lead contributors : (2009) (0)
ALL-326: Low Incidence of Central Nervous System (CNS) Relapse with Hyper-CVAD-R Regimen in Adults with Burkitt Lymphoma/Leukemia (BL) and High-Grade B-Cell Lymphoma (HGBCL) (2020) (0)
Peripheral T-Cell Lymphoma, Not Otherwise Specified (2013) (0)
p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development (2019) (0)
Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells (2020) (0)
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens (2018) (0)
Homoharringtonine and Mebendazole Are Preferentially Lethal Against Models of Myeloid Malignancy Associated with Germline Mutant RUNX1 (2021) (0)
Prognostic Value of Disease Location in Secondary Central Nervous System Diffuse Large B-Cell Lymphoma (2020) (0)
Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Stud (2020) (0)
Patient with mixed-phenotype acute leukemia with CBFB rearrangement (2019) (0)
Grade 3 Follicular Lymphoma Patients Can Experience Favorable Outcomes With Various Management Strategies (2017) (0)
Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy (2021) (0)
Lymphocyte-Depleted Hodgkin Lymphoma (2013) (0)
Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) in Adults: A High-Risk Subtype (2015) (0)
T-Cell Prolymphocytic Leukemia Involving Lymph Nodes and Other Tissues (2013) (0)
Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy (2021) (0)
Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification (2022) (0)
USCAP 2022 Abstracts: General Surgical Pathology (508-521) (2022) (0)
Inflammatory Pseudotumor of Lymph Nodes (2013) (0)
Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. (2015) (0)
Granulomatous solitary pulmonary nodule. (2011) (0)
neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm (2020) (0)
Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor (2019) (0)
Donor Cell-Derived Acute Myeloid Leukaemia with 3q26.2 Involvement/MECOM Rearrangement ‐ A Case Report and Literature Review (2020) (0)
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse (2020) (0)
BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL) (2020) (0)
Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens (2020) (0)
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells (2022) (0)
Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123‐targeted therapy: A novel finding and possible diagnostic pitfall (2020) (0)
Proceedings of the tumor board of St. Jude Children's Research Hospital, Memphis, Tennessee: Gestational choriocarcinoma (2006) (0)
Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens (2016) (0)
Post-transplant Lymphoproliferative Disorder: Early and Polymorphic Lesions (2013) (0)
Lymph Node Infarction (2013) (0)
A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab (2020) (0)
3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features (2023) (0)
Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1-mutated Acute Myeloid Leukemia (2020) (0)
Results of phase 1 clinical trial evaluating efficacy of 3rd party cord blood regulatory T cells for prevention of graft versus host disease. (2018) (0)
Nodal Marginal Zone Lymphoma (2013) (0)
Correction: Chronic myeloid leukemia with insertion-derived BCR–ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis (2020) (0)
Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL) (2017) (0)
Nodular Lymphocyte–predominant Hodgkin Lymphoma With Nodular Sclerosis (2022) (0)
Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS (2022) (0)
From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature. (2021) (0)
Adoptive Cord Blood T Regulatory Cell Therapy Leads to Resolution of Inflammation and Decreased Proteinuria in Lupus Nephritis (2020) (0)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells (2019) (0)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort (2022) (0)
EARLY FINDINGS CREATE BUZZ FOR POTENT NOVEL HORMONE BLOCKER DO YOU KNOW WHERE YOUR PROSTATE CANCER TISSUE IS (2008) (0)
Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML (2019) (0)
Atypical Mycobacterial Lymphadenitis (2013) (0)
Mdm2 Maintains Cholesterol Biosynthesis in Hematopoietic Stem/Progenitor Cells Independent of p53 (2021) (0)
Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence (2022) (0)
Abstract 1071: Targeted therapy evaluation in novel pre-clinicalin vitroandin vivomodels of Richter transformation (2019) (0)
CLL transformation after one cycle of FCR: Richter’s or EBV-associated lympho-proliferation? (2017) (0)
Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia (2022) (0)
Feasibility of pre-operative mTOR inhibitor Sirolimus in children and young adults with desmoid tumor (2019) (0)
Nevus Cell Inclusions (2013) (0)
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) (2022) (0)
B-Lymphoblastic Lymphoma/Leukemia (2013) (0)
Successful Management of Diffuse Large B-Cell Lymphoma Involving the Mesentery with Volumetric Image Guided Intensity Modulated Radiation Therapy (2018) (0)
Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis — Chronic Myelomonocytic Leukemia and Beyond (2021) (0)
DNMT3A mutations exert a dominant adverse effect in De novo acute myeloid leukemia with concurrent FLT3 and NPM1 mutations (2015) (0)
Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis (2018) (0)
From the archives of MD Anderson Cancer Center: Intravascular large B-cell lymphoma with numerous circulating lymphoma cells. (2022) (0)
Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases (2021) (0)
Nasal Intermittent Positive Pressure Ventilation vs Nasal Neurally Adjusted Ventilatory Assist for Apnea, Bradycardia and Desaturations in VLBW Infants (2019) (0)
Radiation Therapy for Salivary Gland MALT Lymphoma: Ultra Low Dose Treatment Spares Salivary Function and Achieves Excellent Outcomes (2018) (0)
Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists (2016) (0)
Silicone-Induced Lymphadenopathy (2013) (0)
MYC, BCL2 and BCL6 co-localisation patterns at single-cell resolution underlie their prognostic significance in diffuse large B-cell lymphoma (2020) (0)
Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. (2022) (0)
Autoimmune Lymphoproliferative Syndrome (2020) (0)
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. (2023) (0)
Chapter 20 – Ewing’s Sarcoma Family of Tumors (2010) (0)
Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease (2013) (0)
Solitary Plasmacytoma of Lymph Node (2013) (0)
Abstract #LB-260: Changes in circulating tumor cells over time correlates with D-dimer and serum prostate-specific antigen levels in patients with refractory prostate cancer. (2009) (0)
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. (2016) (0)
PF672 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) (2019) (0)
Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL) (2017) (0)
Clinicopathologic features of therapy-related myeloid neoplasms in myeloma patients in the era of novel therapies. (2023) (0)
Systemic Lupus Erythematosus Lymphadenopathy (2013) (0)
Is More Always Better? Effects of Patch Sampling in Distinguishing Chronic Lymphocytic Leukemia from Transformation to Diffuse Large B-Cell Lymphoma (2022) (0)
Extramedullary Hematopoiesis in Lymph Nodes (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joseph D. Khoury?

Joseph D. Khoury is affiliated with the following schools:

MD Anderson Cancer Center
American University of Beirut
Johns Hopkins University
Arizona State University
University of Nebraska Medical Center